ResearchPulse (@ResearchPulse1) profile picture
Joined June 2024
Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)Photo by ResearchPulse (@ResearchPulse1)
1/8 CagriSema data – better than the market reaction This is a longer analyse of the CagriSema Redefine 1 data. Enjoy your reading and please don’t hold your comments back. "I will throughout this analyze try and show what that “extra” potential WL looks like. I also zoom in at one of the most often conclusions I have seen. “Only 57% finished the trial at max dose CagriSema. That means it had seriously tough side effects”. I believe that is both a hasty and wrong conclusion." $NVO $LLY $VKTX $GUBRA $ZEAL @GLP1
6
12
2
81
101,121
Wegovy pill will be launched tomorrow in Australia. And prices will be exactly as rumoured 2 weeks ago. $260-395 AUD or about $180-270 USD. At this Tuesdays Danish investor meeting, Mike said launch in Denmark very soon. I still expect Norway, Sweden and Italy be among the next countries. Canada approval should also be close. And that would definitely be a priority country for launch start of January if possible. Especially as Foundayo was just approved in Canada yesterday. I speculate that Health Canada has asked Questions in wegovy pill filing since it’s not approved yet. www1.racgp.org.au/newsgp/cli… $LLY $NVO $VKTX
Wegovy pill price in Australia revealed $260-395 AUD or about $180-270 USD. Same prices as wegovy pen. No launch date revealed yet. We only know it will be before Christmas. Wegovy pill Label includes cardiovascular risk reduction. This is important since $NVO currently has ongoing negotiations for supply of wegovy pen to a subgroup of patients in Australia with high BMI and high cardiovascular risk. With this patient population getting full reimbursement for wegovy. A bit more restrictive inclusion criteria than what NVO has won in UK where up to 1.1 million with high cardiovascular risk can get full reimbursement. When wegovy pill label get the same cardiovascular risk reduction then it might be included (speculative on my part) $LLY $VKTX
2
1
23
2,200
Need a primer on amylin? 🤔 📣 Happy to share our new American Association of Clinical Endocrinology (AACE) Module: Preparing for Change: Amylin Science and Emerging Hormone-Based Obesity Therapies 🔬 In this module series we discuss: 🔹Physiologic role of amylin in energy balance, appetite regulation, and metabolic control, and how it complements other hormonal pathways involved in obesity. 🔹 Emerging clinical evidence on amylin-based therapies and their potential role in the future management of obesity. 🔹 Evolving amylin science into a broader, mechanism-based framework for individualized obesity treatment 🔗 Module Link: pro.aace.com/education-and-e…
2
2
21
1,465
Wait did $NVO CEO just raise their 2030 growth projections….. Those who follow NVO knows NVO SP got hammered at CMD at the second they announced their very lowballing 2030 growth projections. NVO ceo said they expect to grow in line with peers which is yearly mid single digit percentage growth until 2030. It did not take many seconds from saying that until SP got hammered. And CMD had only just begun with 6 hours more to go. But that 2030 growth projections was like someone put up the biggest loudspeaker you can think about and they just blasted white noise the rest of the CMD Even though there was plenty great nuggets throughout the day, that 2030 “guidance” took all headlines and made several analysts downgrade future growth. The complete opposite results of what the company had expected. But apparently NVO CEO just said they aim for higher growth than peers…. So higher than yearly mid single digit percentage growth through 2030. He apparently even said they are determined to outperform its competitors…... 😳 Even if we don’t include $LLY , then this is overall much more “agressiv” than the very disappointing and lowballing CMD projections. What a difference two month have made. This was said a few hours ago at Danish Shareholders Association's Investordagen event. Now I hope journalists and analysts follow up so this more upbeat 2030 growth projections can be confirmed (or not) and get public. $LLY
Speaking at the Danish Shareholders Association's Investordagen event, $NVO CEO Mike Doustdar discussed the company's long-term growth ambitions and its efforts to regain investor confidence. At its Capital Markets Day in September, Novo Nordisk announced a target of delivering sales growth in line with the pharmaceutical industry through 2030, corresponding to mid-single-digit annual growth. However, Mike Doustdar made it clear that the company is aiming higher. He explained that management's responsibility is to establish realistic targets it believes it can achieve and then work hard to exceed them. The comments come after a challenging period for Novo Nordisk, marked by increasing competition in obesity treatments, disappointing clinical trial results, and significant management changes. In response, the company has shifted toward a more consumer-focused commercial strategy in 2026. This includes lower prices, partly through agreements with the Trump administration, combined with an emphasis on reaching significantly more patients. The strategy is based on generating higher sales volumes to compensate for lower prices. Novo Nordisk has also gradually improved its 2026 outlook throughout the year. What initially looked like a year of declining sales and earnings has developed into expectations of approximately flat performance. Mike Doustdar also emphasized that Novo Nordisk is determined to outperform its competitors. He made it clear that everyone at the company, including himself, wants to beat the competition and is actively looking for ways to achieve that. For investors, the interesting takeaway is that Novo Nordisk's mid-single-digit growth target through 2030 should not necessarily be interpreted as management's ultimate ambition. Mike Doustdar appears determined to rebuild confidence by setting achievable expectations and then delivering results above them. Whether Novo Nordisk can achieve that will depend on its ability to grow patient volumes, compete effectively with $LLY , and successfully launch new treatments over the coming years.
7
1
2
45
9,850
$NVO has quietly started concrete research and development of molecules for Rare Bone disorders and also the much larger osteoporosis. Yesterday NVO published research on DACRA (amylin) that potentially could help reduce loss of bone mass and thereby delay or reduce impact on postmenopausal osteoporosis in women @rn_flex We briefly talked about this a few days ago But as $NVO also emphasis this is still early exploration. DACRA has not reached proof of concept yet. They have multiple trials ongoing where they try to validate any actual evidence of bone preservation. Not only through bio markers $LLY $VKTX
Could CagriSema also help preserve bone health? $NVO While I were asleep😴, $NVO presented additional research at #ObesityWeek 2026 exploring the potential effects of its amylin-based medicines on bone health. And there is one patient group for whom these findings could be particularly relevant: postmenopausal women. Declining oestrogen levels after menopause accelerate bone loss and increase the risk of osteoporosis and fractures. At the same time, substantial weight loss can also affect bone metabolism. Some of the key findings: 🦴 Preclinical data: In a model of postmenopausal bone loss, cagrilintide and CagriSema significantly attenuated the loss of trabecular bone and deterioration of bone microarchitecture. Trabecular bone volume in the femur was: • 43% higher with cagrilintide • 40% higher with CagriSema Both compared with weight-matched controls. 🧬 Human biomarker studies: Cagrilintide and zenagamtide suppressed CTX-I, a marker of bone resorption. Interestingly, the selective amylin receptor agonist NN1213 did not show the same effect. This suggests that activation of both the amylin and calcitonin receptors may play an important role. 📊 REDEFINE 1: Post hoc analyses showed that BMD decreased with CagriSema during substantial weight loss, as expected, but remained within the normal range for age and sex at week 68. Researchers also observed changes in proteins involved in bone formation and mineralisation that were not seen with semaglutide alone. The potential ability to combine substantial weight loss with a more favourable effect on bone metabolism could become an important differentiator for amylin-based treatments. And particularly for postmenopausal women, who may already be at increased risk of osteoporosis, this is an important area worth investigating. Imagine a treatment that not only helps patients lose substantial amounts of weight but may also help preserve bone health along the way. Source: ml-eu.globenewswire.com/Reso… $NVO $LLY
2
35
3,242
$NVO just released results from P3 with wegovy in children’s aged 6-12. WL up to 17.4% More than 70 million children agede 5-9 lives with obesity. 100 million agede 10-19 lives with obesity Treating children as young as 6 year with GLP1 is for sure a controversial subject. Should children just learn how to eat healthy. To exercise…… That has been, and is to some extent, still what some means when adults are using GLP1 like Wegovy and Zepbound. But as an adult we decide for ourselves. With Young children it will be adults choosing for them. Would you give children (your son/daughter) GLP1 if that could help them lose weight? With reduced weight could also potentially follow a number of positively social changes for the child. Opposite there’s not 50 million years of safety data for children like there is for adults using semaglutide. There’s not right or wrong answers in this somewhat controversial subject @ManOnThePen $LLY $VKTX
A new milestone for $NVO: semaglutide demonstrates significant efficacy in children as young as 6. Novo Nordisk has announced positive Phase 3 results from the STEP Young trial, evaluating semaglutide in children aged 6 to under 12 with obesity. After 68 weeks: • −17.4% BMI reduction with semaglutide vs. +2.2% with placebo (efficacy estimand). • −13.5% vs. +2.7% using the treatment regimen estimand, accounting for treatment discontinuation. • 83% improved their BMI category, compared with 23.5% on placebo. • 40.4% were no longer classified as having obesity, compared with 0% on placebo. More than 85% of participants had severe obesity at baseline. Importantly, Novo reported no unexpected safety concerns and no identified concerns regarding growth or pubertal development. This is about more than weight reduction. Childhood obesity can have lifelong consequences, and effective treatment options for this age group remain limited. STEP Young expands Novo’s clinical evidence across the obesity spectrum — from adults and adolescents to children as young as six. The treatment is still investigational for children under 12, and regulatory approval will be needed. Source: Novo Nordisk, 16 November 2026; The New England Journal of Medicine. $NVO $LLY #ObesityWeek SourcE: ml-eu.globenewswire.com/Reso…
5
1
26
2,131
ResearchPulse retweeted
December 20, 2024. A date that changed the story for $NVO. Make coffee and read this! That was the day Novo Nordisk released the first results from REDEFINE 1. CagriSema delivered 22.7% weight loss after 68 weeks (efficacy estimand) — below the market’s expectations, after Novo had previously communicated a potential 25%. The market’s reaction was brutal. Novo lost 688B DKK (101B USD) in marketcap that day. The share price fell from DKK 692 to an intraday low of DKK 484, before closing at DKK 546 — a decline of almost 21% on the day. Trading volume reached approximately 26 million shares on the Copenhagen exchange. And the decline did not stop there. But fast-forward to #ObesityWeek 2026, and the picture is becoming more nuanced. Novo has now presented additional data from REDEFINE 1 showing that 67.8% of CagriSema patients were early responders, achieving at least 5% weight loss within just eight weeks. These early responders had an observed mean weight loss of 25.4% at week 68. That's more then 25%! Another important finding: 73.1% reported a meaningful improvement in physical function, compared with 49.1% on placebo. Meaningful improvements in psychosocial function were also reported by 69.0%, versus 42.1% on placebo. And then there is REDEFINE 9. CagriSema delivered approximately 21% weight loss at 68 weeks even at the lower 1.0/1.0 mg and 1.7/1.7 mg doses. Importantly, the treatment-regimen results — which account for treatment discontinuation — were still 18.6% and 19.4%, respectively. These are not just numbers on a scale. The market is increasingly recognising that obesity treatment is about much more than the percentage of weight lost. The broader clinical value matters too. #Semaglutide, one of CagriSema’s two components, already has substantial evidence beyond weight reduction: • Cardiovascular: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease. • Kidney protection: The FLOW trial demonstrated a 24% reduction in the risk of major kidney outcomes in people with type 2 diabetes and chronic kidney disease. • Liver disease: The ESSENCE trial showed significant improvements in MASH resolution and liver fibrosis with semaglutide 2.4 mg. These are semaglutide data — not yet outcomes demonstrated specifically for CagriSema. But they illustrate the broader therapeutic value of the molecule that is already part of the combination in CagriSema. Following the ObesityWeek developments, $NVO is trading at DKK 287.50, up 3.24% today. The stock has been through an extraordinary repricing. The question is whether the market has become so focused on the initial disappointment that it is underestimating the longer-term potential of CagriSema. Perhaps the market is slowly beginning to look at the whole picture again. They new journey just started! $NVO $LLY
2
4
34
3,525
ResearchPulse retweeted
🇨🇳 Novo Nordisk has secured national reimbursement for IcoSema (insulin icodec + semaglutide), making China the first country to provide reimbursement for this innovative once-weekly combination. At the same time, Awiqli (insulin icodec) has secured renewed reimbursement with an expanded coverage scope for patients with type 2 diabetes. A few key points: 🔹 IcoSema enters China's national reimbursement list from January 1, 2027. 🔹 Novo is already lowering regional list prices to bring the benefits to patients ahead of implementation. 🔹 Awiqli's reimbursement coverage is expanded to type 2 diabetes patients. More access, stronger commercial positioning — although pricing and margins will be important to watch. Source: baby.ifeng.com/c/8y2uw4xykK0 $NVO #NovoNordisk #Diabetes
1
9
993
ResearchPulse retweeted
Wegovy HD hit a record 25,758 weekly TRx, week ending 6 Nov. +2.0% on the week vs +0.4% for all Wegovy Pen. Down in only 2 of 31 weeks since launch. Annualised run-rate ~$530m. $NVO
2
3
1
15
4,373
Good to see wegovy pill back to setting new records again. $LLY $NVO $VKTX
Wegovy pill hit a record 185,366 weekly TRx, week ending 6 Nov, its 3rd straight up week. Adjusted for IQVIA capture (62% pill, 90% Foundayo): Wegovy pill ~299k Foundayo ~77k Foundayo also set a record (+6.6%), but Novo's oral lead is still ~3.9x. $NVO $LLY
1
1
38
2,357
New post-hoc analysis of CagriSema Redefine 1 There’s a lot of talk or should I say noise about loss of lean mass. Loss of lean mass is the wrong metric to run with. Its functional strengths that matters. Are you better or worse to move around after a big WL. Are you better or worse to handle everyday life from a functional perspective. Walk on stairs, get up from sitting position etc. I think we will see much more focus on functional strengths after WL like with this CS abstract from Obesity week. Also from molecules with new MoA. Some will even promote increasing muscle strength and mass. The sort of molecules that will end up at anti doping lists. GubUCN2 from $Gubra is one of that type of molecule. $LLY $NVO $VKTX
$NVO has released two additional post-hoc analyses from REDEFINE 1, presented at #ObesityWeek 2026. A few interesting findings: 🔹 67.8% of CagriSema-treated participants achieved at least 5% weight loss within just 8 weeks. 🔹 Early responders achieved an observed mean weight loss of 25.4% at week 68, compared with 17.8% among delayed responders. 🔹 73.1% reported a meaningful improvement in physical function, versus 49.1% on placebo. 🔹 Meaningful improvements in psychosocial function were also reported by 69.0% versus 42.1% on placebo. Important caveat: These are post-hoc analyses, and the findings should be considered hypothesis-generating. Still, another interesting addition to the growing CagriSema evidence base. Source: ml-eu.globenewswire.com/Reso… $NVO #ObesityWeek $LLY
1
1
14
1,722
CagriSema Redefine 9 side effects. Look at placebo arm between Redefine 9 and redefine 1. R9 reports in general much higher share of side effects than R1 (that had higher 2.4mg dose ) across active arms as well as placebo no arms. So in general difficult to compare across these trials. $LLY $NVO $VKTX
CagriSema Redefine 9 Baseline data. 1mg 80% women 1.7mg 83% women Placebo 70% women So very high share of women vs 68% women in Redefine 1.
1
7
1,751
CagriSema Redefine 9 Baseline data. 1mg 80% women 1.7mg 83% women Placebo 70% women So very high share of women vs 68% women in Redefine 1.
We now have a bit more data from CagriSema R9. Now also ITT data Efficacy data (those who stayed throughout trial) 1/1mg 21% WL 1.7/1.7mg 20.7% WL ITT data 1/1mg 18.6% WL 1.7/1.7mg 19.4% WL Very few drop out in 1.7mg. That’s why ITT for 1.7mg is better than 1mg that had better efficacy WL I speculate there’s higher share of women in 1mg than 1.7mg $LLY $NVO $VKTX novonordisk.com/news-and-med…
4
1
12
3,243
We now have a bit more data from CagriSema R9. Now also ITT data Efficacy data (those who stayed throughout trial) 1/1mg 21% WL 1.7/1.7mg 20.7% WL ITT data 1/1mg 18.6% WL 1.7/1.7mg 19.4% WL Very few drop out in 1.7mg. That’s why ITT for 1.7mg is better than 1mg that had better efficacy WL I speculate there’s higher share of women in 1mg than 1.7mg $LLY $NVO $VKTX novonordisk.com/news-and-med…
CagriSema Redefine 9 will be presented tomorrow at Obesity week. Abstract has been released today, and now we get some clues about the high WL with lower doses 1/1mg (21.0%) and 1.7/1.7mg (20.7%)vs Redefine 1 which were 2.4/2.4mg (22.7%) Small study with only 309 patients. 77% women vs 68% in R1. We don’t yet know the share in each arm 39BMI vs BMI 38 in R1 That seems likely to be part of the reason why the smaller doses reach this high WL vs R1 $LLY $NVO $VKTX
6
1
39
4,503
This is really interesting. A CVS analysis shows that GLP1 could become cost neutral with prices below $350 per month. Big employers could easily get below that price by bypassing PBMs. I don’t understand why we do not hear more about employers going this road. @JCanNuSH do you have more insight into how this market develops? We hear about several new companies offer such services. But very little about how many employers choose this path to significantly reduce prices for GLP1. It will be very interesting to follow Bridge developments. To succeed it needs to show a path towards cost reduction in healthcare by using GLP1. $LLY $NVO $VKTX
💰 What is the real economic value of GLP-1 treatments? $NVO $LLY A new CVS Health analysis offers an interesting perspective. According to CVS, GLP-1 treatments could become cost-neutral for employers and health plans at prices below $350 per month. Some key findings: 🔹 10–12% fewer emergency room visits during the first and second year of treatment. 🔹 34–42% fewer hospitalisations among patients still on treatment after three years. 🔹 Over three years, health plans saved $9,400 per patient in medical costs — but spent $13,300 more on prescriptions. Net result: $3,900 in additional costs per patient. The important point? The economic return depends on the patient's risk profile. Older patients with diabetes may generate savings much faster than younger patients with obesity alone. This is an important part of the GLP-1 pricing debate. The value is not just weight loss — it's potentially reducing the broader burden on healthcare systems. Source: Reuters, November 14, 2026 reuters.com/legal/litigation… $NVO $LLY #OW2026 #ObesityWeek
3
17
3,047
ResearchPulse retweeted
GLP-1 tracker updated! TRx for week ending October 30, 2026. Foundayo at week 31 of launch. Wegovy pill at week 44 of launch. - Wegovy pill = 185,366 TRx - Foundayo = 69,323 TRx Wegovy pill to Foundayo = 2,67x TRx Same launch periods, Wegovy pill to Foundayo: 1. 2.21x 2. 4.97x 3. 4.65x 4. 3.89x 5. 3.73x 6. 3.41x 7. 4.17x 8. 4.33x 9. 4.08x 10. 4.12x 11. 4.61x 12. 5.12x 13. 5.39x 14. 4.67x 15. 4.65x 16. 4.59x 17. 4.18x 18. 3.52x 19. 3.88x 20. 3.57x 21. 3.03x 22. 3.36x 23. 3.44x 24. 2.85x 25. 2.33x 26. 2.64x 27. 2.45x 28. 2.93x 29. 2.72x 30. 2.66x 31. 2.35x $NVO $LLY
1
2
9
1,057
CagriSema Redefine 9 will be presented tomorrow at Obesity week. Abstract has been released today, and now we get some clues about the high WL with lower doses 1/1mg (21.0%) and 1.7/1.7mg (20.7%)vs Redefine 1 which were 2.4/2.4mg (22.7%) Small study with only 309 patients. 77% women vs 68% in R1. We don’t yet know the share in each arm 39BMI vs BMI 38 in R1 That seems likely to be part of the reason why the smaller doses reach this high WL vs R1 $LLY $NVO $VKTX
5
1
30
5,873
Ozempic pill grew about 0.7% this week to about 68,1K according IQVIA. Up from about 50k before Rybelsus rebranding to Ozempic pill. Run rate above $1.4B before launch of 25mg Ozempic pill in January. Expected approval in December Ozempic pen was up 0.5% this week and Mounjaro up by 0.4% $LLY $NVO $VKTX
Ozempic pill was up by 1.8% to about TRx 67.6K with last weeks IQVIA data. Up by about 35% since rebranding Rybelsus to Ozempic pill. ASP for Ozempic pill is about 2x of Wegovy pill. So the increase has a bit larger impact than what the TRx numbers suggest when comparing with wegovy pill. As a reminder 25mg Ozempic pill will be approved in December with launch in January backed up by a larger promotion campaign. $LLY $NVO $VKTX
1
29
1,830
Wegovy HD grew 2% this week to about TRx 25,800. More than 110K consumers now using HD. Run rate above $535 million in US. Wegovy pen overall grew with 0.4%. HD keeps outgrowing week by week. $LLY $NVO $VKTX
30
2,055
Ouch Foundayo P3 trial in Japan. Efficacy estimand 11.8% WL 7.9% ITT for top dose. Only 73% (efficacy) at top dose reached 5% WL Disclaimer. I don’t have the publication so can’t see gender distribution BMI etc that can influence the data. $LLY $NVO $VKTX
Efficacy and safety of oral #orforglipron in Japanese participants with #obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial thelancet.com/journals/landi… #weightloss #GLP-1 receptor agonist
9
1
45
6,316